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ABSTRACT
We have recently shown that non-viral gene therapy
can stabilise the decline of lung function in patients
with cystic ﬁbrosis (CF). However, the effect was
modest, and more potent gene transfer agents are still
required. Fuson protein (F)/Hemagglutinin/
Neuraminidase protein (HN)-pseudotyped lentiviral
vectors are more efﬁcient for lung gene transfer than
non-viral vectors in preclinical models. In preparation
for a ﬁrst-in-man CF trial using the lentiviral vector, we
have undertaken key translational preclinical studies.
Regulatory-compliant vectors carrying a range of
promoter/enhancer elements were assessed in mice and
human air–liquid interface (ALI) cultures to select the
lead candidate; cystic ﬁbrosis transmembrane
conductance receptor (CFTR) expression and function
were assessed in CF models using this lead candidate
vector. Toxicity was assessed and ‘benchmarked’
against the leading non-viral formulation recently used
in a Phase IIb clinical trial. Integration site proﬁles were
mapped and transduction efﬁciency determined to
inform clinical trial dose-ranging. The impact of pre-
existing and acquired immunity against the vector and
vector stability in several clinically relevant delivery
devices was assessed. A hybrid promoter hybrid
cytosine guanine dinucleotide (CpG)- free CMV
enhancer/elongation factor 1 alpha promoter (hCEF)
consisting of the elongation factor 1α promoter and
the cytomegalovirus enhancer was most efﬁcacious in
both murine lungs and human ALI cultures (both at
least 2-log orders above background). The efﬁcacy (at
least 14% of airway cells transduced), toxicity and
integration site proﬁle supports further progression
towards clinical trial and pre-existing and acquired
immune responses do not interfere with vector efﬁcacy.
The lead rSIV.F/HN candidate expresses functional CFTR
and the vector retains 90–100% transduction efﬁciency
in clinically relevant delivery devices. The data support
the progression of the F/HN-pseudotyped lentiviral
vector into a ﬁrst-in-man CF trial in 2017.
INTRODUCTION
Our ongoing efforts to improve pulmonary gene
transfer for the treatment of lung diseases such as
cystic ﬁbrosis (CF) have led to the assessment of a
lentiviral vector (simian immunodeﬁciency virus
(SIV)) pseudotyped with the Sendai virus (SeV)
envelope proteins F and HN (rSIV.F/HN).1 The
latter contribute signiﬁcantly to the high transduc-
tion efﬁciency of SeV-based vectors in the airway
epithelium.2
We have previously shown that F/HN-pseudotyped
SIV vector produced gene expression in the lungs
and nose of mice for the duration of their lifetime
Key messages
What is the key question?
▸ Is a lentiviral vector, which was pseudotyped to
achieve efﬁcient gene transfer into airway
epithelial cells, suitable for progression into a
ﬁrst-in-man gene therapy trial in patients with
cystic ﬁbrosis (CF)?
What is the bottom line?
▸ The data support the progression of the F/
HN-pseudotyped lentiviral vector into a
ﬁrst-in-man CF trial in 2017 for which funding
has been obtained.
Why read on?
▸ In contrast to other viral vectors, lentiviral
vectors hold substantial promise for the
development of gene therapy for a range of
diseases, including chronic conditions due to
their high efﬁcacy, duration of expression and
the fact that pre-existing and acquired immune
responses do not interfere with vector efﬁcacy
on repeated administration.
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(∼2 years). Further, this expression was at least 2-log orders higher
than our lead non-viral formulation recently shown to produce
signiﬁcant effects in the lungs of patients with CF. Repeated daily
administration led to a cumulative dose-related increase in gene
expression, while repeated monthly administration to murine
lower airways was feasible without loss of gene expression. There
was no evidence of chronic toxicity during a 2-year study period
and F/HN-pseudotyped SIV led to persistent gene expression in
human differentiated airway cultures and human lung slices and
transduced freshly obtained primary human airway epithelial
cells.3 4 In contrast to other pseudotypes, such as vesicular stoma-
titis virus glycoprotein (VSV-G)5 or GP64,6 the F/HN pseudotype
does not require coadministration of compounds that open tight
junctions or inhibit ciliary beating,3 4 likely making the vector
more acceptable for clinical translation in the context of CF
chronic pulmonary bacterial infection.
It has been suggested that self-inactivating (SIN) lentiviral
vectors may carry less risk of insertional mutagenesis due to
inactivation of the promoter/enhancer properties in the long-
terminal repeat (LTR) which were responsible for proto-
oncogene transactivation in some γ-oncoretroviral vector
trials.7 In the most studied context of haematopoetic stem cells
(HSCs), differences in insertion site (IS) proﬁles between
γ-oncoretroviral and lentiviral vectors have favoured the
safety proﬁle of the latter.7 8 Further, recent studies with
γ-oncoretroviral9 and lentiviral10 vectors in patients with
Wiskott–Aldrich syndrome have allowed, for the ﬁrst time,
direct comparison of safety and efﬁcacy of these vectors in
man. Until now, the data support an improved safety proﬁle of
lentiviral vectors in the context of HSC transduction. Further,
clinical studies in patients with metachromatic leukodystro-
phy11 and Parkinson’s disease12 have not raised any safety con-
cerns for lentiviral vectors, although longer follow-up is
required.
To catalyse translation of the lentiviral vector platform into
clinic, we have now selected the clinical lead candidate by gener-
ating pharmacopoeia-compliant producer plasmids and
cGMP-compliant vector production methods (Virus Production
paper; in preparation) and comparing several promoter/enhancer
elements in both integrase-competent (IC) and integrase-
defective (ID)13 vectors in mouse lung and ex vivo human
models. Further, we have (a) mapped integration sites, (b) charac-
terised transduced cell types, (c) assessed acute toxicity, (d) deter-
mined the effects of pre-existing immunity on transduction
efﬁciency and toxicity, (e) assessed CFTR function of our lead
vector and (f) quantiﬁed vector stability in delivery devices suit-
able for a ﬁrst-in-man trial. We propose that this combined body
of data supports the progression of the rSIV.F/HN vector into a
ﬁrst-in-man CF clinical trial.
MATERIALS AND METHODS
See online supplementary material.
Statistical analysis
All analyses were performed using GraphPad Prism6. Parametric
and non-parametric data distributions were assessed with the
Kolmogorov-Smirnov normality test. Multiple group and
two-group comparisons were performed using appropriate stat-
istical tests for speciﬁc data sets (see details in individual ﬁgure
legends). In ﬁgure 1B, C, cross-sectional statistical analysis was
performed on a selected time point and, therefore, no adjust-
ments for longitudinal correlations were made. The null hypoth-
esis was rejected at p<0.05.
RESULTS
Selection of lead candidate vector from murine and human
tissue studies
Our previously published studies were carried out with IC
vectors using the cytomegalovirus (CMV) immediate early
promoter/enhancer to regulate gene expression.3 4 Here, we
compared the CMV promoter/enhancer with the eukaryotic
elongation factor 1α (EF1α) promoter and a chimeric regula-
tory element consisting of the human CMV enhancer coupled
to the EF1α promoter (hCEF), with the aim to select the most
efﬁcient construct for progression into clinical trials (see
online supplementary material for details on vector produc-
tion). All experiments were performed with the maximum
feasible volume/dose and vector titres for each conﬁguration
(see online supplementary table S1 for details). The hCEF-IC
vector conﬁguration achieved the highest and most persistent
gene expression in the murine lung and nose (p<0.001) when
compared with all other constructs 130 days after transduc-
tion (ﬁgure 1A–C). This ∼3 month time point was predeﬁned
for cross-sectional analysis, based on previous data. The ID
vector conﬁgurations did not differ from untreated (UT)
controls.
Air–liquid interface (ALI) cultures were also transduced with
the ﬁve vector conﬁgurations ranging from 6 to 30E7 TU/ALI
(n=4/group). The ID vector conﬁguration did not differ from
UT controls, but all three IC conﬁgurations lead to signiﬁcant
(p<0.005 for CMV-IC and EF1α-IC, and p<0.0001 for
hCEF-IC at day 5 when compared with controls) levels of gene
expression on day 5, which persisted for the hCEF-IC vector to
day 14 (p<0.01). Consistent with data from mice, the hCEF-IC
conﬁguration achieved the highest and most persistent gene
expression in ALIs (ﬁgure 1A, D) and was consequently selected
as the lead candidate for progression into clinical trials with the
designation rSIV.F/HN-hCEF from here onwards.
Gene expression occurs in relevant airway epithelial cells
Murine lungs were transduced with rSIV.F/HN-hCEF carrying
the enhanced green ﬂuorescent protein (EGFP) cDNA and gene
expression quantiﬁed histologically. Representative sections of
airway and alveolar regions are shown in ﬁgure 2A, B.
Approximately 15% of the target airway epithelial cells through-
out the lung expressed EGFP (ﬁgure 2C).
To further characterise the range of cells that rSIV.F/
HN-hCEF-EGFP transduced, double labelling using a range of
cell-type-speciﬁc antibodies was performed (see online supple-
mentary table S2). Figure 3 shows that the vector was also able
to transduce goblet and club cells, as well as type I and II pneu-
mocytes and on rare occasions basal cells. We could not detect
EGFP expression in pulmonary macrophages.
rSIV.F/HN shows a similar acute toxicology proﬁle
to liposome transfection
We have previously shown that F/HN-pseudotyped lentiviral
vector administration to murine lung does not cause chronic toxi-
city.4 Here, we show that the survival kinetics of mice treated
with various vectors manufactured using regulator-compliant,
animal-product-free, production methods did not differ from
vehicle-treated littermates and the animals remained healthy on
gross observation (see online supplementary ﬁgure S1).
We next assessed the acute toxicity 24 hours after a single
administration, as well as 24 hours after the ﬁnal of four monthly
doses of rSIV-F/HN. Mild cellular inﬁltrates were observed in all
groups treated with lentivirus (representative image shown in
ﬁgure 4A). However, these responses (ﬁgure 4B) were of similar
magnitude to those produced by the non-viral formulation, which
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was recently used in a Phase IIb multidose trial and did not result
in any signiﬁcant toxicity in patients with CF14 and were not sig-
niﬁcantly different to changes seen in control animals.
Insertion site analysis
Integration site frequency analyses calculated by GREAT using
regions deﬁned as integration site ±10 kb and integration site
±100 kb showed that 73% and 70%, respectively, of each were
between 5 and 500 kb from transcription start sites (TSS) (see
online supplementary ﬁgure S2 and the Results section in the
online supplementary data). Although there are insufﬁcient inte-
gration sites to draw deﬁnitive conclusions, an exploratory onto-
logical survey revealed no preference for integration near
oncogenic loci (data not shown).
Figure 1 Selection of lead candidate vector. Mice and human air–liquid interface (ALI) cultures were transduced with ﬁve different lentiviral vector
conﬁgurations by nasal instillation: integrase-competent (IC) vectors carrying the human elongation factor 1α (short) promoter (EF1α),23 a
ubiquitous regulatory element which has previously been used in the context of lentivirus-mediated gene transfer,48 an in-house, synthetic chimeric
promoter/enhancer consisting of CpG-depleted versions of the human EF1α (short) promoter and the human cytomegalovirus (CMV) enhancer
(hCEF)24 and the original CMV-based construct, as well as integrase-defective (ID) vectors carrying the CMV promoter and hCEF promoter/enhancers
(6–30E7 TU/mouse or ALI, n=6–10 mice/group, n=4 ALI/group). All vectors carried a luciferase reporter gene for quantiﬁcation of gene expression
by bioluminescence imaging. Negative control mice and ALIs remained untreated (UT). Gene expression was quantiﬁed in the lungs and nose of
mice and in ALIs. Photon emission adjusted for differences in vector titre. (A) Representative images of transduced and UT mice and ALIs,
(B) quantiﬁcation of photon emission in murine lungs, (C) quantiﬁcation of photoemission in murine nose and (D) in human ALIs. (B–D) Reference
UT control values are shown as a dotted line (lung control: 182±6 p/s/cm2/sr, nose control: 200±10 p/s/cm2/sr, ALI control 598±1080 p/s/cm2/sr). For
each group, the mean±SEM are shown. ****p<0.001 in lung and nose comparing hCEF-ID with all other vectors in mice (ANOVA followed by
Tukey post hoc test), ***p<0.005 comparing hCEF-IC with UT ALI controls (Mann–Whitney).
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Effects of acquired immunity and pre-existing immunity
In the context of viral gene transfer, acquired immunity and pre-
existing immunity to the vector are important considerations.
We, and others, have previously shown that in contrast to other
viral vectors, lentiviruses can be repeatedly administered at
doses that are in a likely therapeutic range.3 4 15
Acquired immunity—induction of rSIV.F/HN neutralising
antibodies?
We ﬁrst conﬁrmed that the pharmacopoeia-compliant vector
conﬁguration and serum-free production methods did not affect
the efﬁcacy of repeat administration (three doses at monthly
intervals) (Virus Production paper; in preparation). As part of
these experiments, we also quantiﬁed neutralising antibodies
using an in vitro transduction inhibition assay and showed that
antibodies neutralising rSIV.F/HN, but not a vector pseudotyped
with the vesicular stomatitis virus G glycoprotein (r.SIV.VSV-G,
negative control) neutralising antibodies were detectable in
serum of mice 28 days after a single dose of rSIV.F/HN (see
online supplementary ﬁgure S3).
Pre-existing immunity—passive immunisation of mice with
human Ig
The key F and HN proteins on rSIV.F/HN are derived from SeV
which has high sequence homology with human parainﬂuenza
virus 1 (hPIV1).16 17 Approximately 70–90% of people have
been infected with hPIV1 and produce anti-hPIV1 antibodies.
We, therefore, assessed whether the presence of anti-hPIV1 anti-
bodies altered transduction efﬁciency and toxicity in mice. We
ﬁrst incubated rSIV.F/HN with either puriﬁed IgG or IgA
anti-hPIV antibodies; both inhibited the transduction of rSIV./F/
HN in vitro (see online supplementary ﬁgure S4).
To assess the in vivo signiﬁcance of these ﬁndings, mice were
then treated with human Igs (IVIg) intraperitoneally or topically
to the lung by nasal snifﬁng. The doses achieved, and indeed
exceeded, antibody titres measured in human broncho alveolar
lavage ﬂuid (BALF) and serum (see online supplementary ﬁgure
S5). Unsurprisingly, intraperitoneal (IP) administration of IVIg
leads to higher antibody levels in serum, whereas intratracheal
administration leads to higher titres in BALF.
We next treated mice with IVIg IP and intranasally (IN) as
described above, followed 24 hours later by rSIV.F/
HN-hCEF-EGFPLux. There was no signiﬁcant reduction in
gene expression in the nose or lung 7 days (ﬁgure 5) or 28 days
after transduction (data not shown).
We also assessed the potential toxicity arising from the inter-
action of rSIV.F/HN with the preformed hPIV1 antibodies. Gross
observation showed that transduced mice pretreated with IVIg
were indistinguishable from non-IVIg-treated mice. In addition,
we monitored temperature in the acute phase immediately post
virus administration and did not observe differences in any of the
groups (see online supplementary ﬁgure S6A). Further, animal
and lung weights did not differ in any of the groups (see online
supplementary ﬁgures S6B, C).
Pre-existing immunity–SeV-induced anti-F and HN antibodies
To further assess the effect of pre-existing immunity to the key F
and HN epitopes, mice were challenged with SeV prior to trans-
duction with rSIV.F/HN. Mice were transduced with two doses
(1 month apart) of transmission-incompetent SeV18 19 (1E6 or
1E7 TU/mouse/dose) followed by one dose of rSIV.F/
HN-hCEF-EGFPLux. We conﬁrmed that high levels (p<0.001)
of anti-SeV antibodies were generated in BALF and serum after
SeV transduction (see online supplementary ﬁgure S7E); trans-
duction with rSIV.F/HN also increased (p<0.001) anti-SeV anti-
bodies in serum. There was no difference in any of the groups
(see online supplementary ﬁgure S7A–D) with respect to weight,
food and water consumption or body temperature over time.
Figure 2 Gene expression in relevant
airway epithelial cells. Mice were
transduced with rSIV.F/HN-hCEF-
enhanced green ﬂuorescent protein
(EGFP) (8E8 TU/mouse) or remained
untreated (UT) (n=3/group). Seven days
after transduction, mice were culled and
the lungs processed for quantiﬁcation of
airway cells expressing EGFP by
immunohistochemistry. (A) Representative
image of a lentivirus transduced mouse.
(B) Representative image of an UT mouse.
Scale bar=50 mm. AW, airway; P,
parenchyma. (C) Quantiﬁcation of EGFP in
mouse airways. Each dot represents a
randomly selected airway (n=10/mouse).
For convenience, the data from the UT
control mice were pooled. The horizontal
bar shows the median. The dotted
horizontal line represents the consensus
therapeutic threshold of 5% airway cells.
****p<0.0001 comparing all treated
mice with controls (ANOVA followed by
Dunnett’s multiple comparison test). GFP,
green ﬂuorescent protein.
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Pre-existing immunity—neutralising activity of anti-hPIAV1
in human serum
We next quantiﬁed endogenous anti-hPIV1 IgG levels in serum
from adults and children to enable IgG positive and negative
samples to be selected for the in vitro transduction inhibition
assay (see online supplementary ﬁgure S8A). rSIV.F/HN
transduction was inhibited by anti-hPIAV1 IgG positive and
negative samples (see online supplementary ﬁgure S8B–E). In
contrast, and similar to the in vitro data obtained using murine,
rSIV.VSV-G-mediated transduction was signiﬁcantly (p<0.01)
less affected conﬁrming epitope speciﬁcity (see online supple-
mentary ﬁgure S8F).
Figure 3 Characterisation of
transduced cells by
immunohistochemistry. Mice were
transduced with rSIV.F/
HN-hCEF-enhanced green ﬂuorescent
protein (EGFP) (8E8 TU/mouse) or
remained untreated (n=3/group). Seven
days after transduction, mice were culled
and the lungs processed for
characterisation of EGFP-expressing cells
by immunohistochemistry. Tissue sections
were double-stained with anti-EGFP and
cell-type-speciﬁc antibodies and DAPI to
visualise nuclei (blue). The left panel
shows EGFP-expressing cells in green, the
middle panel shows cell-type-speciﬁc
staining in red and the right panel shows
a merged image. Arrows highlight
double-labelled cells. The merged images
do not in all cases show a yellow/orange
signal when green and red signals are
overlaid because the proteins stained are
localised to different cellular
compartments, for example, in type 1
pneumocytes, the EGFP is present in the
cytoplasm, whereas podoplanin is a
membrane protein. Scale bar=10 mm. (A)
Anti-β tubulin antibody identiﬁes ciliated
airway epithelial cells, (B)
anti-uteroglobin antibody identiﬁes club
cells in the airways, (C) anti-mucin 5AC
antibody identiﬁes goblet cells in the
airways, (D) anti-cytokeratin 5 antibody
identiﬁes basal cells in the airways,
(E) anti-podoplanin antibody identiﬁes
type 1 pneumocytes and (F)
anti-surfactant protein C antibody
identiﬁes type 2 pneumocytes.
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Figure 4 Assessment of acute pulmonary toxicity after lentivirus transduction. Mice were transduced with one or four doses (1E8 TU/dose at
monthly intervals, n=5/group) of rSIV.F/HN-cytomegalovirus vectors carrying luciferase or enhanced green ﬂuorescent protein reporter genes and
histological analysis was performed 24 hours after the last dose. Control groups included UT and D-PBS-treated mice and mice treated with
conventional (CpG containing) luciferase plasmid DNA/GL67A complexes or CpG-free CFTR plasmid pGM169/GL67A (n=3–5 mice/group). (A)
Representative image of a lentivirus-treated mouse. AW, airway, P, parenchyma, arrow indicates mild cellular inﬁltrate, (B) semiquantitative scoring
of lung inﬂammation. UT, untreated, one dose of rSIV (rSIV1x) and four monthly doses of rSIV (rSIV4x). Each symbol represents an individual mouse.
The horizontal bar indicates the group median.
Figure 5 Transduction efﬁciency in mouse lung and nose in the presence of anti-human human parainﬂuenza virus 1 (hPIV1) antibodies. Mice
were treated with human Ig (IVIg) intraperitoneally (IP, 400 μL) or by nasal instillation (IN, 100 μL). Controls did not receive IVIg (n=6/group).
Twenty-four hours after passive immunisation, mice were transduced with rSIV.F/HN-hCEF-EGFPLux (1E8 TU/mouse). Control mice remained
untreated (UT). Luciferase expression was quantiﬁed in lung and nose using bioluminescent imaging 24 hours after virus transduction.
(A) Representative images for each cohort of mice, (B) luciferase expression nose and (C) lung. Each symbol represents one animal. The horizontal
bar indicates the group median. Two independent experiments were performed (n=6/group/experiment) and a representative ﬁgure is shown. EGFP,
enhanced green ﬂuorescent protein; GFP, green ﬂuorescent protein.
6 Alton EWFW, et al. Thorax 2016;0:1–11. doi:10.1136/thoraxjnl-2016-208406
Cystic ﬁbrosis
group.bmj.com on November 18, 2016 - Published by http://thorax.bmj.com/Downloaded from 
Pre-existing immunity—neutralising activity of anti-hPIAV1
in epithelial lining ﬂuid
To address whether these endogenous anti-hPIV1 antibodies in
epithelial lining ﬂuid (ELF) may inhibit rSIV.F/HN transduction
in vivo, we ﬁrst quantiﬁed anti-hPIV1 IgG and IgA antibodies in
BALF from children and adults’. Approximately 5% of children
and 35% of adult samples were positive for anti-hPIV1 IgG,
while 47% of children’s and 44% of adults’ samples were posi-
tive for anti-hPIV1 IgA (see online supplementary ﬁgure E9A).
We next grouped subjects into: IgG+/IgA+(n=4), IgG+/IgA−
(n=5), IgG−/IgA+ (n=15) and IgG−/IgA− (n=17) and under-
took in vitro transduction inhibition assays on 31 out of the 41
samples. The average % inhibition was 36±17%, 22±13%, 10
±4% and 12±4% for the four groups, respectively.
Subsequently, antibody positive samples (irrespective of type)
were pooled and compared with antibody negative samples.
There was no signiﬁcant difference between the groups, suggest-
ing that the low levels of inhibition seen were unlikely to be
anti-hPIV1 antibody speciﬁc (see online supplementary ﬁgure
S9B). As a control, we also assessed transduction inhibition of a
VSV-G-pseudotyped control virus in a subset of samples, which
was not different from rSIV.F/HN, suggesting that the modest
inhibition is unrelated to anti-hPIV1 antibodies.
CFTR expression and function after rSIV.F/HN-hCEF-CFTR
transduction
We have previously shown that F/HN-SIV expressing CFTR
under the CMV promoter generates CFTR chloride channels as
assessed by the iodide efﬂux assay in vitro.3 Here, we ﬁrst con-
ﬁrmed that the lead candidate rSIV.F/HN-hCEF carrying a
codon-optimised and cytosine guanine dinucleotide (CG)
nucleotide-depleted CFTR cDNA (soCFTR2) also generated
cyclic Adenosine Monophosphate (cAMP)-dependent CFTR
chloride channels in this assay (ﬁgure 6A).
We next transduced the nasal epithelium of CF knockout
mice with rSIV.F/HN-hCEF-CFTR and detected signiﬁcant
levels of vector-speciﬁc mRNA at both 7 (p<0.005) and 28
(p<0.01) days (ﬁgure 6B). We also transduced CF knockout
mice with rSIV.F/HN-hCEF-CFTR (5E7 TU/mouse, n=10) and
assessed nasal potential difference at time points ranging from 7
to 90 days post transduction, but were unable to document cor-
rection of the chloride transport defect at this titre (data not
shown, see online supplementary material for further
discussion).
Forskolin-induced swelling of human intestinal organoids has
recently been shown to be an accurate readout for CFTR
channel activity.20 We ﬁrst assessed whether rSIV.F/HN-hCEF
carrying a secreted GLux reporter gene could transduce non-CF
organoids. High levels of GLux expression were detected in all
treated samples (see online supplementary ﬁgure S10). We next
transduced CF organoids with rSIV.F/HN-hCEF-CFTR. We
observed that organoid swelling increased signiﬁcantly
(p<0.0001) in rSIV.F/HN-hCEF-CFTR-treated cultures com-
pared with negative controls (ﬁgure 7A–D). These functional
data were supported by western blot detection of CFTR protein
in CF organoids (ﬁgure 7E). In conclusion, the data indicate
that lentiviral delivery of CFTR in CF intestinal organoids par-
tially restores their CF characteristics.
Vector stability in clinically relevant delivery devices
Vector stability was assessed in a range of delivery devices suit-
able for administration of lentivirus to the nose or a restricted
region in the lungs of patients with CF. Ultimately, we anticipate
the vector to be delivered via an aerosol-generating nebuliser to
the whole lung. However, ﬁrst-in-man safety and
proof-of-concept studies may focus on local and directed
delivery of the vector to the nasal and airway epithelium. We
therefore assessed vector stability in two catheters and in a nasal
spray bottle and showed that passage through these devices did
not reduce transduction efﬁciency (see online supplementary
ﬁgure S11). Thus, clinically relevant delivery devices suitable for
administration to the nose as well as for regional lung delivery
have been identiﬁed.
DISCUSSION
In addition to the use of SIN vectors, the regulation of gene
expression by internal promoter/enhancer elements, rather than
by the viral LTRs appears to have signiﬁcantly improved biosaf-
ety of the vectors21 and has highlighted the importance of opti-
misation of the expression cassettes in improving efﬁcacy. We
compared the strong CMV promoter/enhancer (recently used in
Parkinson’s disease trials22), the human EF1α short promoter (a
commonly used ubiquitous eukaryotic promoter capable of per-
sistent transgene expression in the lung following non-viral gene
Figure 6 Conﬁrmation of CFTR expression and function. (A) HEK293T cells were transfected with rSIV.F/HN-hCEF-CFTR or an irrelevant control
virus (negative control) at MOIs of 10 and 100. The iodide efﬂux assay was performed 2 days after transduction. Data are presented as mean±SEM.
**p<0.05 compared with negative control (ANOVA followed by Dunnett’s multiple comparison test). (B) Cystic ﬁbrosis knockout mice were
transduced with rSIV.F/HN-hCEF-CFTR (1.6E8 TU/mouse) by nasal instillation. Negative controls were treated with PBS (n=7–8/group). Mice were
culled 7 and 28 days after vector administration and vector-speciﬁc mRNA was quantiﬁed in the lungs. Each symbol represents one animal. The
horizontal bar shows the group median. The dotted line indicates the detection limit of the assay. ***p<0.005 and **p<0.01 compared with the
negative control (Kruskal-Wallis followed by Dunn’s multiple comparison test).
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transfer)23 and a CpG-free hybrid promoter (hCEF) consisting
of the EF1α promoter and the human CMVenhancer, which we
initially developed for, and have recently used in, our Phase IIb
non-viral CF gene therapy trial.14 24 The hCEF regulatory
element led to the highest levels of gene expression in the
murine lung and nose in vivo as well as in human ALI cultures.
However, we noted good consistency between murine lung and
nose as well as the human ALI models and these data may help
inform future strategies for screening promoter/enhancer ele-
ments for lung delivery. As part of our screening strategy, we
also compared standard IC and ID vectors. In our models, the
proﬁle of low transient expression from the ID vector conﬁgura-
tions did not support further assessment.
It is likely that the hCEF regulatory element leads to higher
than physiological expression of CFTR in transduced cells.
Although it has been shown that CFTR overexpression can
affect cell proliferation rates in vitro, transgenic mice overex-
pressing CFTR showed no adverse effects.25 In addition, we
have not seen any evidence of CFTR-related toxicity in our
recent multidose non-viral gene therapy trial, which also used
the hCEF regulatory element.14
Using our lead candidate conﬁguration, approximately 15%
of relevant target epithelial were transduced at the titres we
were able to generate for these studies. This compares favour-
ably with a broadly held view that between 5% and 25% of
cells may require correction to provide a meaningful level of
clinical correction. The titre of 8E8 TU of
rSIV-F/HN-hCEF-EGFP used to generate these data will form
the basis for estimating suitable dose ranges for the ﬁrst-in-man
clinical trial.
In addition to ciliated airway epithelial cells, a range of other
cell types, including goblet and club cells, as well as type I and
II pneumocytes were transduced. Consistent with our previous
data in the nasal epithelium,3 we conﬁrmed that basal cells,
likely progenitor cells located in the subepithelial layer, were
only infrequently transduced. We did not see any evidence for
transduction of pulmonary macrophages, the preferential cell
type transduced by VSV-G-pseudotyped lentivirus when applied
to the mouse lung by bolus administration and without the add-
ition of a tight junction opener.26 The broad transduction range
of rSIV.F/HN is not surprising considering that recombinant
SeV similarly transduces a wide range of cell types.27 In the
human lung, the range of transduced cell types will likely
depend on the delivery method. For example, aerosols with
droplet sizes of 3–5 μm, which are most suitable for airway
delivery, will, for example, not lead to efﬁcient vector depos-
ition in the alveoli.
Consistent with our previous ﬁndings, transduction with
pharmacopoeia-compliant vectors did not cause chronic or
excessive acute toxicity. The mild neutrophilic inﬁltrates
Figure 7 Functional conﬁrmation of CFTR production in cystic ﬁbrosis (CF) intestinal organoids. (A–D) CF intestinal organoids carrying two class I
mutations (E60X/4015delATTT) were transduced with rSIV.F/HN-hCEF-CFTR or an irrelevant control virus (negative control). The doses in experiment
1 ranged from 0.45 to 3.6E7 TU/well and in experiment 2 from 0.06 to 0.45E7 TU/well (n=4/dose/experiment). Doses greater than 1.8E7 TU/well
resulted in cell toxicity and reduced chloride transport (as measured by reduced organoid swelling upon forskolin addition) (data not shown).
Analysis of chloride transport in the CF organoids 4 days after transduction therefore focused on samples treated with 0.23–0.9E7 TU/well (n=15–16
wells/group in two independent experiments). Four days post-transduction, organoid swelling upon addition of forskolin was assessed (measured as
area under curve (AUC) over 120 min, baseline set at t=0). Representative organoid images are shown. Data are presented as mean±SEM.
****p<0.0001 compared with negative control (non-paired Student’s t-test). (E) At the end of the experiment, organoids were harvested for protein
extraction and western blot analysis. Lane 1: non-CF organoids transduced with negative control virus, Lanes 2–4: CF organoid untransduced or
transduced with a negative control virus and Lane 5: CF organoids transduced with rSIV.F/HN-hCEF-CFTR.
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observed in mouse lung were of similar magnitude to those pro-
duced by our non-viral formulation pGM169/GL67A, which
has already been assessed in a multidose Phase IIb trial.14
Oncogenesis through viral genome integration is intrinsically
less likely in terminally differentiated cells of the airway epithe-
lium than it is in rapidly dividing cells of the haematopoetic
lineage. We infer from this preliminary study that there is no
obvious bias in the distribution of integration site at the chromo-
somal level; the integration pattern in relation to TSS is similar
to that reported for an SIV-based vector in primary haematopoi-
etic stem cells by Nienhuis et al.28 Given the terminally differen-
tiated nature of the airway epithelium, it is notable that the
ﬁndings are broadly consistent with lentiviral integration site dis-
tributions in the eye and brain,29 30 suggesting that the genotoxi-
city risk of rSIV.F/HN vectors in the airways is comparably low.
Acquired and pre-existing immune responses have affected
the use of adenoviral-associated and adeno-associated virus
vectors for airway gene transfer.31 32 We and others have previ-
ously shown4 15 that lentiviral vectors can be repeatedly admi-
nistered. We also show that repeated administration is feasible
despite detection of anti-rSIV.F/HN neutralising antibodies in
serum. It is difﬁcult to make quantitative comparisons between
antibody levels obtained in this and other studies due to the
variability of the in vitro transduction inhibition assays used.
However, Sinn et al15 reported that induction of humoral
immune responses after lentivirus pulmonary gene transfer was
signiﬁcantly lower than after adenovirus-mediated gene transfer
to the lung. It is currently unclear whether repeated administra-
tion of lentiviral vectors is feasible because of (a) low immuno-
genicity, (b) rapid cell entry thereby avoiding contact with
neutralising antibodies or (c) due to other reasons. It is also
unclear how well animal models will predict responses in man.
In the context of Adeno-associated virus (AAV)-mediated liver
transduction, it has become clear that murine models did not
predict immune responses in man.33
To assess the effects of pre-existing human antibodies that
may cross-react with the F and HN proteins and affect efﬁcacy
and toxicity, we pretreated mice with human Igs (IVIg) which
contain anti-hPIAV1 IgG. IVIg was administered either IP or IN
and the dosing strategy achieved hPIAV1 antibody titres in
ranges representative of titres in human serum and BALF. The
presence of pre-existing hPIV antibodies did not alter the trans-
duction efﬁciency or safety in mice. In contrast, it has previously
been shown that IVIg preadministration (12 mg/mouse) drastic-
ally reduces AAV-mediated gene transfer to the liver,34 thereby
validating the use of human antibodies in murine models.
The cause of death of a participant in an early adenovirus
clinical trial in 1999 has been widely debated.35 One suggestion
is that the presence of high level, pre-existing, anti-adenovirus
antibodies may have led to complement activation after vector
administration initiating a severe immune reaction.36 To assess
whether pre-existing antibodies to F and HN proteins alter rSIV.
F/HN toxicity, we pretreated mice with two doses of SeV prior
to lentivirus transduction and did not observe enhanced toxicity
compared with controls.
The majority of humoral response against hPIV is mediated by
IgG and IgA antibodies.37 IgA is the predominant Ig in the upper
respiratory tract where it is locally synthesised by plasma cells in
the lamina propria. IgG is the main Ig isotype in blood and in the
lower respiratory tract. We, therefore, next assessed transduction
inhibition of rSIV.F/HN in human serum samples that were either
positive or negative for anti-hPIV1 IgG and showed that trans-
duction inhibition occurred in both hPIV1 ELISA positive and
negative samples, whereas the transduction with rSIV.VSV-G was
not inhibited. The reasons for the inhibition in hPIV1 negative
samples may relate to sensitivity of the ELISA assay or cross-
reactivity with antibodies directed against other hPIV serotypes,
which the hPIV-speciﬁc ELISA would not have detected, but
could affect the transduction efﬁciency. We then assessed trans-
duction inhibition in BALF which contains IgG (derived from
blood) and IgA (produced locally in the lung). We analysed
anti-hPIAV1 IgG/IgA positive and negative samples and did not
detect evidence for rSIV.F/HN-speciﬁc inhibition. We have previ-
ously determined that lavage ﬂuid represents an approximately
40-fold dilution of the ELF using a standard urea assay (data not
shown) and this may affect interpretation of the results.
However, Moss et al38 detected anti-AAV2 neutralising anti-
bodies in BALF of patients with CF treated with AAV2 and
Bastian and Bewig39 showed that anti-adenovirus neutralising
antibodies can be detected in human BALF, thus supporting the
notion that vector neutralising antibodies can be detected in
BALF despite the ELF dilution factor.
We have previously shown that F/HN-SIV vector expressing
CFTR under the control of the CMV promoter generated
cAMP-dependent ion transport in an in vitro iodide efﬂux
assay3 and here conﬁrmed these data for the pharmacopoeia-
compliant rSIV.F/HN vector carrying the soCFTR2 cDNA. In
addition, we demonstrated rSIV.F/HN transduction and CFTR
function in a recently developed intestinal organoid model.20
We also showed that rSIV.F/HN-hCEF-CFTR transduces the
nasal epithelium of CF knockout mice efﬁciently (∼100% vector-
speciﬁc mRNA compared with endogenous murine Cftr mRNA).
CF mice do not acquire spontaneous airway infections or
develop CF lung disease, but the nasal epithelium shows the
characteristic CF chloride and sodium transport defects.40 To
further assess CFTR function, we attempted to correct ion
transport in the CF mouse nasal epithelium, but were unable to
do so. For these experiments, we used a dose of 5E7 TU/mouse
(maximum feasible dose based on vector availability). We
cannot exclude the possibility that this titre may have been sub-
therapeutic. However, the relevance of measurement of CFTR
function in the murine nose (via in vivo potential difference)
has been called into question by Ostrowski et al41 who showed
that expression of human CFTR under the transcriptional
control of a cilia-speciﬁc promoter did not correct ion transport
in CF knockout mice. In addition, Grubb et al42 have suggested
that the olfactory, rather than the respiratory, nasal epithelium
mainly contributes to the ion transport defect in CF mice.
Considering these data, we do not expect an increase in vector
dose to alter chloride secretion because we have previously
shown that our vector does not efﬁciently transduce olfactory
epithelial cells.3 We have also shown that the CF mouse is of
limited value as a stepping stone to human gene therapy trials.
Although GL67A-mediated CFTR gene transfer partially cor-
rected chloride transport in the human lung and nose, reduced
bacterial adherence to epithelial cells and decreased interleukin
(IL)-8 and neutrophils in CF sputum,43 we were unable to
correct a panel of CFTR-speciﬁc endpoint assays in the murine
nose, including ion transport, periciliary liquid height and ex
vivo bacterial adherence.44 Our data are also consistent with an
earlier study by Jiang et al,45 who showed that
GL67A-mediated gene transfer did not lead to correction of the
ion transport defect in CF mice and our own report of success-
ful correction of chloride transport in the human, but not in the
murine, nose after transfection with DC-Chol/DOPE.46 47
Taken together, these data suggest that the CF knockout mouse
may not be a representative model in which to assess gene trans-
fer efﬁciency to human airway epithelial cells and that
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correction of ion transport in mice should not be used as a
go-no-go decision point for progression into clinical trial. We
have also considered the two CF pig models that have been
developed, but these animals currently die shortly after birth
due to intestinal disease and, therefore, are (a) not available in
large enough numbers to conduct meaningful studies and (b)
not compatible with the time course of lentivirus integration
and gene expression.
In preparation for a ﬁrst-in-man trial, which will involve
regional delivery of vector to the airways, we assessed vector sta-
bility in a range of delivery devices suitable for focal delivery.
The virus was stable in these ‘single-pass’ delivery devices. We
will conduct a single-dose, double-blinded, dose-escalating
Phase I/IIa safety and efﬁcacy clinical study. A total of 24 adult
subjects will be recruited into four groups receiving 1E8, 5E8
and 2.5E9 TU of rSIV.F/HN-hCEF-CFTR or placebo. Dosage
levels were determined principally by considering the titre
necessary to demonstrate gene expression in the mouse nose,
the target for therapeutic expression in humans (5% cells trans-
duced) and the interspecies scaling factor. The trial will not be
designed to detect clinical efﬁcacy, but will focus on assessing
safety and the time course of CFTR expression and function.
In summary, in combination with the parallel development of
scalable good manufacturing practices (GMP)-compliant vector
production methods, we suggest that the mouse and ex vivo
human data presented here support the progression of rSIV.F/
HN into a ﬁrst-in-man clinical study for CF scheduled to start
in 2017. In addition, the unique feature of this vector platform
also opens opportunities for other lung and systemic diseases.
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